Australia TGA Listed Medicines: AUST L, Permitted Ingredients, Permitted Indications and Lifecycle Readiness

Listed Medicines are regulated under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 as low-risk therapeutic goods suitable for self-selection by consumers. Listing requires (1) all active and excipient ingredients on the Permitted Ingredients Determination with use within the specified quantity, route, dosage form and target population limits; (2) all indications drawn from the Permitted Indications list (a closed list of approximately 1,300 permitted indications spanning structure/function, vitamin/mineral health maintenance, traditional indications across Western herbal, Traditional Chinese Medicine, Ayurvedic and other paradigms); (3) sponsor (the Australian-resident entity legally responsible for the product) holding sufficient quality, safety and efficacy evidence available on request; (4) manufacturing site holding TGA GMP licence (Australian manufacturer) or GMP Clearance (overseas manufacturer); (5) electronic listing submission via the Electronic Listing Facility (ELF) with sponsor self-certification of compliance with all requirements. Listings are typically issued within days or weeks of submission rather than the months/years of full Registered Medicines pre-market assessment. The trade-off is the closed ingredient and indication framework — products outside the Permitted Ingredients or Permitted Indications scope cannot use the Listed pathway and require AUST L(A) or full Registered pathway. Post-market compliance review by TGA is active, with random and targeted compliance audits, and finding rates historically substantial driving the importance of pre-market sponsor due diligence.

The Therapeutic Goods (Permissible Ingredients) Determination is the legal instrument listing every ingredient permitted for use in Listed Medicines, with per-ingredient conditions including maximum daily dose, route of administration (oral, topical, inhalation), target population restriction, dosage form restriction, mandatory warning statements where applicable, and specific quality requirements (e.g. heavy metal limits, microbiological limits, identity verification methods). The Determination is updated periodically — typically twice yearly — through a TGA public consultation process; new ingredient applications take 12-24 months and require substantial safety dossier. Common scope issues: ingredient form variations (different salts, different botanical preparations, different extraction methods) may have separate Determination entries or fall outside the listed entries requiring application; ingredient combinations may carry combination-specific restrictions; population restrictions (children, pregnancy, lactation) may exclude product positioning; warning statement requirements may conflict with brand marketing approach. Sponsor due diligence before listing submission is essential — listing a product with an ingredient outside the Determination triggers TGA non-compliance action including cancellation, retrospective recall and potential prosecution under the Act.

The Therapeutic Goods (Permissible Indications) Determination is the closed list of approximately 1,300 permitted indications for AUST L Listed Medicines. The list is organised across general health maintenance, vitamin and mineral function (deficiency support), Western herbal traditional, Traditional Chinese Medicine traditional, Ayurvedic traditional, aromatherapy and homoeopathic indications. Each indication has specified wording that the sponsor must use verbatim — variation in wording is non-compliant. Traditional indications must be accompanied by the qualifier 'traditionally used' or equivalent to signal the traditional rather than clinical evidence basis. Indications outside the Permitted Indications list cannot be used in Listed Medicines — products requiring such indications must use the AUST L(A) Listed Assessed pathway or full Registered Medicines pathway. The AUST L(A) pathway introduced in 2018 allows intermediate-risk indications subject to TGA pre-market efficacy evaluation — the sponsor submits efficacy evidence, TGA reviews and assesses the indication, and the resulting AUST L(A) Listed Assessed Medicine carries the assessed indication with a distinctive consumer-facing mark indicating TGA efficacy review. AUST L(A) timelines are months rather than weeks but materially shorter than full Registered Medicines and the pathway has gained traction for differentiated indications outside the Permitted Indications scope.

Listed and Registered Medicines must be manufactured in TGA-licensed facilities under the PIC/S Guide to GMP for Medicinal Products. Australian manufacturers hold a Therapeutic Goods Act manufacturing licence issued by TGA following on-site inspection. Overseas manufacturers — most supplement Listed Medicines are sponsor-imported with overseas manufacture — require GMP Clearance, obtained through one of three pathways: (1) Mutual Recognition Agreement (MRA) Clearance for manufacturers in jurisdictions with TGA mutual recognition (EU, UK, Switzerland, Canada, US for some categories) using the overseas regulator's GMP certification; (2) Compliance Verification (CV) Clearance using TGA's assessment of overseas regulator GMP inspection reports for non-MRA jurisdictions with acceptable GMP frameworks; (3) Inspection-based Clearance via direct TGA inspection of the overseas site, used where MRA and CV pathways are unavailable. Clearance is product-category specific and time-limited, typically 3 years. Sponsor responsibility for ongoing GMP Clearance maintenance, change management at the manufacturing site, and recall and adverse event handling is non-delegable. Major commercial risk events include lapse of GMP Clearance during the renewal cycle (causing ARTG cancellation for affected SKUs), overseas regulator GMP inspection finding cascading to TGA action, and contract manufacturer change without prior Clearance for the new site.

Listed Medicines lifecycle obligations include (1) annual fee payment per listing to TGA to maintain ARTG status — lapsed annual fee triggers automatic cancellation; (2) post-market compliance review — TGA conducts targeted and random compliance reviews of Listed Medicines with finding rates historically substantial (the 2018-2019 TGA compliance review programme reported non-compliance rates of around 50-80% across reviewed products driving the post-market focus); findings include ingredient out of Permitted Ingredients scope, indication out of Permitted Indications scope, label discrepancy, evidence inadequacy on review request, manufacturer GMP status drift; (3) Therapeutic Goods Advertising Code compliance — Australia operates a strict therapeutic goods advertising framework with TGA enforcement, prohibition of testimonials for certain product categories, restrictions on prizes and incentives, and substantial penalties for non-compliant advertising; the Therapeutic Goods Advertising Hub provides current code and complaint pathways; (4) recall and Uniform Recall Procedure for Therapeutic Goods compliance for any safety event; (5) adverse event reporting — sponsors must maintain pharmacovigilance and submit serious adverse events to TGA. The recurring compliance investment is substantial; sponsors maintaining a portfolio of Listed Medicines typically employ dedicated TGA-experienced regulatory affairs personnel.